Corporate Research Fronts> June 2010
June 2010
This list of corporate research fronts from Essential Science IndicatorsSM from Thomson Reuters is from the sixth bimonthly period of 2009, and covers areas in the biological sciences. Source dates are January 31, 2004-December 31, 2009, the sixth bimonthly period of 2009 (sliding 6-year period).
| Research Front Name | % of corp. affiliations | Leading corp. |
|---|---|---|
| RECOMBINANT HUMAN APOPTOSIS LIGAND 2/TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (RHAPO2L/TRAIL); FULLY HUMAN TRAIL-RECEPTOR 1 MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR-1 | 50 | Genentech, Inc |
| METABOLITE IDENTIFICATION; LIQUID CHROMATOGRAPHY/HYBRID QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETRY; EARLY DRUG DISCOVERY; HIGH-RESOLUTION LIQUID CHROMATOGRAPHY/QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETRY | 40 | Waters Corp |
| VIRTUAL SCREENING; PROTEIN-LIGAND DOCKING; EVALUATING VIRTUAL SCREENING METHODS; VIRTUAL LIGAND SCREENING; VIRTUAL SCREENING USING MULTIPLE BIOACTIVE REFERENCE STRUCTURES; SIMILARITY-BASED VIRTUAL SCREENING USING 2D FINGERPRINTS | 31 | Schrodinger, LLC |
| TYPE 2 DIABETES FAILING THIAZOLIDINEDIONE MONOTHERAPY; TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED; TYPE 2 DIABETES INADEQUATELY CONTROLLED; DIPEPTIDYL PEPTIDASE IV INHIBITOR VILDAGLIPTIN SUPPRESSES ENDOGENOUS GLUCOSE PRODUCTION | 30 | Merck & Co, Inc |
| THERAPEUTIC RNAI TARGETING PCSK9; PLASMA CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 NEUTRALIZING ANTIBODY REDUCES SERUM CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR DECREASES RECEPTOR RECYCLING | 29 | Amylin Pharmaceuticals, Inc |
| ABERRANT P53 SIGNALING; SMALL-MOLECULE MDM2 ANTAGONISTS; MDM2 ANTAGONISTS ACTIVATE P53; SUPPRESS LETHAL P53 ACTIVITY IN-VIVO; P53 RESTORATION; ACTIVATES P53 FUNCTION | 26 | Hoffmann La Roche Inc |
| HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR; HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS; HEPATITIS C VIRUS NS3-4A SERINE PROTEASE; RESISTANT GENOTYPE 1 HEPATITIS C VIRUS REPLICATION; NOVEL HEPATITIS C VIRUS PRO-TEASE INHIBITOR | 25 | Vertex Pharmaceuticals Inc |
| PERCUTANEOUS CORONARY INTERVENTION; STENT THROMBOSIS; PROTON PUMP INHIBITORS FOLLOWING ACUTE CORONARY SYNDROME; ELECTIVE PERCUTANEOUS CORONARY INTERVENTION; PLANNED PERCUTANEOUS CORONARY INTERVENTION; PRASUGREL ACHIEVES GREATER INHIBITION | 24 | Eli Lilly & Co |
| HERBICIDE-RESISTANT CROPS; TEN YEARS; GLYPHOSATE-RESISTANT CROPS; IMIDAZOLINONE-TOLERANT CROPS; EVOLVED GLYPHOSATE-RESISTANT WEEDS; WEED RESISTANCE | 21 | BASF Corp |
| 2003-2009_6 | ||
Corporate Research Fronts
Research Fronts
About
Featured Image:
REUTERS/Bonoit Tessler